Data protection Impressum

Personalized Medicine

This investment propels Aktiia's mission to address the global challenge of hypertension, which affects over 1.4 billion individuals worldwide and is responsible for more than 18 million deaths annually.

Aktiia secures CHF 27 million to combat global hypertension crisis

4 March 2024

SmellRS is developing an ambitious and innovative technology for the early detection of Alzheimer's disease and the restoration of the sense of smell.

FONGIT Innovation Fund backs HeroSupport and SmellRS to advance healthcare innovation

4 March 2024

CSEM and ClexBio, a Nordic startup specializing in regenerative medicine, has developed a novel bioreactor capable of cultivating human veins in the laboratory.

CSEM and ClexBio unveil groundbreaking bioreactor to advance cardiovascular treatment

26 February 2024

This collaboration marks a significant leap forward, combining Multiwave's pioneering portable MRI device, MGNTQ, with the University's research prowess.

Multiwave Technologies forges a research partnership with Aix-Marseille University

19 February 2024

This significant financial backing underscores the potential of Alys's comprehensive pipeline targeting a broad spectrum of dermatological indications, from atopic dermatitis to psoriasis.

Alys Pharmaceuticals launches in Geneva with USD 100 million investment

19 February 2024

The breakthrough comes from the University's Autophagy Laboratory, where Prof. Patricia Boya and her team, in collaboration with the Spanish Margarita Salas Center for Biological Research (CIB-CSIC), have demonstrated the potential of specific drugs to stimulate mitophagy, thereby enhancing the ability of cells to "clean house" even as they age.

University of Fribourg discovers drug to combat age-related neuroinflammation

12 February 2024

Onward Therapeutics’ move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.

Onward Therapeutics enters clinical phase with innovative cancer immunotherapy

30 January 2024

This achievement, part of the PILATUS First-In-Human Clinical study (ClinicalTrials ID: NCT06119607), marks a new era in the field of valve replacement.

Novostia successfully implants its TRIFLO Heart Valve Implant in first human patient

24 January 2024

Timeline’s new funding round, led by BOLD (Business Opportunities for L’Oréal Development), includes strategic investments from industry giants L’Oréal and Nestlé.

Timeline secures CHF 56 million to propel its pioneering role in longevity and healthy aging

24 January 2024

Nicolas Collin, Co-Founder and CEO of the Vaccine Formulation Institute (VFI), discusses the innovative approach and global impact of their work in developing high-quality, accessible adjuvants for vaccines and why Geneva was chosen as the ideal location for VFI's impactful work.

Why the Vaccine Formulation Institute chose Western Switzerland

23 January 2024

1 … 3 4 5 6 7 8 9 10 11 … 17